Clinical Trial Update: Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

TYRA-300 is being investigated in a Phase 2 trial for FGFR3-altered low-grade, intermediate-risk non-muscle-invasive bladder cancer; the study is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• TYRA-300

Snippet

Sponsor: Tyra Biosciences, Inc | Conditions: Low-grade NMIBC, FGFR Gene Amplification | Phase 2 | Status: RECRUITING